


Open Orphan facing up to Covid challenge



www.openorphan.com

Open Orphan plc (ORPH:AIM), a leader in testing vaccines and antivirals using human challenge trials. With operations in London, Paris and the Netherlands it is positioned for rapid growth as the world focuses on infectious diseases.

DELIVERING ON ITS PIPELINE

Over the past 12 months Open Orphan has successfully delivered on its pipeline of contracts with major pharma businesses, as such, its state of the art 24-bed quarantine clinic is fully booked until December 2021. To meet demand, Open Orphan opened a new 19-bed quarantine clinic in February 2021, the Whitechapel Clinic was converted on an innovative and low-cost basis.

The company is also a partner in the world's first



COVID-19 human challenge programme, which will be run from a 19-bed ward at the Royal Free Hospital in London. The study is being backed

by the UK Government and received ethics approval in February 2021.

SUPPORTING COVID-19 VACCINE DEVELOPMENT

Open Orphan is now the undisputed world leader in the commercial delivery of challenge studies which involve infecting healthy volunteers with a virus in a controlled quarantine setting to test vaccine efficacy, can potentially speed up vaccine development by two to three years, can test vaccine efficacy on specific variants of a virus



Shares Spotlight Open Orphan

and are far cheaper than large field studies. As Covid-19 has shown, all of these benefits are critical to vaccine development.


With the emergence of new mutations/variants of Covid-19, there is now an urgent need to rapidly develop a second-generation of vaccine against Covid-19 which will bring more human challenge clinical trial work to Open Orphan.

As has been widely reported, second-generation vaccines such as Codagenix COVI-VAC may provide immunity for five to seven years, protect against new variants and only require a single, intranasal dose and don't require deep freeze storage temperatures which hinders the effectiveness of roll-out. COVI-VAC is currently in phase I at Open Orphan's London clinic.

To meet demand, Open Orphan has opened new volunteer recruitment centres in London and Manchester by making use of spaces not currently in use due to the pandemic, increasing volunteer screening capacity by 520 slots per week. To find out more visit the dedicated volunteer recruitment website, www.flucamp.com. Individuals interested in taking part in the COVID-19 characterisation study can visit www.UKCovidChallenge.com to learn more.

SIGNIFICANT NEW GROWTH OPPORTUNITIES

Open Orphan has been developing its Disease in Motion® platform which includes the world's largest database of infectious disease progression data which can power wearables. The digital platform is now patented



with applications for big tech and wearables; pharma and biotech companies.

The Company is also actively working towards the monetisation of its non-core assets: Imutex, Prep Biopharm and Immune modulator.

Since its formation, Open Orphan has consistently delivered on its objectives and was recently listed as a top 10 European CRO (contract research organisation).

The delivery of pipeline from a broad customer base and winning of major contracts including the Covid-19 Human Challenge Programme has resulted in the group reaching profitability in 2020. With global healthcare investment increasing, Open Orphan is in a strong position to deliver value for its shareholders and continues in the months and years ahead to be one of the fastest growing stocks on the London and Dublin exchanges.

"Looking ahead, I am extremely excited by the potential for this business, we have entered a decade of significant spending on vaccines and antivirals by both governments and pharma companies around the world."

"The Open Orphan Group is ideally positioned to capitalise on this increase in vaccine development expenditure."

Cathal Friel, Executive Chairman

